RE:RE:RE:RE:Evolv SP Down 10% today.I don't think the products are formally up against each other..they are separate independent reports to see if the product does what they say they can do. It's up to the readers to decide which product is better or better suited for specific use cases/market opportunities. Even if both products fare well..Pat will benefit the most imo. Evolv's continued sales is evidence that the product works...Pat doesn't have that same volume in sales or big names so this will be the first time shareholders have an independent party validating that the product does what mgmt tells us it does. So Pat has the most to benefit from this...but make no mistake..only significant sales will move the share price significantly and sustain those gains.